Compile Data Set for Download or QSAR
Report error Found 131 Enz. Inhib. hit(s) with all data for entry = 11602
Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596723(CHEMBL5205903 | US20230348421, Compound 59)
Affinity DataIC50: 0.540nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631393(US20230348421, Compound 18)
Affinity DataIC50: 1.12nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631390(US20230348421, Compound 13)
Affinity DataIC50: 1.92nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596721(CHEMBL5178732 | US20230348421, Compound 60)
Affinity DataIC50: 1.93nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596729(CHEMBL5189473 | US20230348421, Compound 82)
Affinity DataIC50: 1.95nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596723(CHEMBL5205903 | US20230348421, Compound 59)
Affinity DataIC50: 2.04nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596732(CHEMBL5200074 | US20230348421, Compound 37)
Affinity DataIC50: 2.05nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631396(US20230348421, Compound 21)
Affinity DataIC50: 2.10nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596721(CHEMBL5178732 | US20230348421, Compound 60)
Affinity DataIC50: 2.11nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631391(US20230348421, Compound 14)
Affinity DataIC50: 2.17nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596722(CHEMBL5172822 | US20230348421, Compound 78)
Affinity DataIC50: 2.17nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596726(CHEMBL5184906 | US20230348421, Compound 55)
Affinity DataIC50: 2.23nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596727(CHEMBL5198741 | US20230348421, Compound 62)
Affinity DataIC50: 2.35nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631406(US20230348421, Compound 45)
Affinity DataIC50: 2.42nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596736(CHEMBL5197899 | US20230348421, Compound 24)
Affinity DataIC50: 2.54nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631430(US20230348421, Compound 81)
Affinity DataIC50: 2.78nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596721(CHEMBL5178732 | US20230348421, Compound 60)
Affinity DataIC50: 3.05nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596730(CHEMBL5184297 | US20230348421, Compound 47)
Affinity DataIC50: 3.13nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631409(US20230348421, Compound 48)
Affinity DataIC50: 3.14nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631418(US20230348421, Compound 61)
Affinity DataIC50: 3.32nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596736(CHEMBL5197899 | US20230348421, Compound 24)
Affinity DataIC50: 3.49nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596729(CHEMBL5189473 | US20230348421, Compound 82)
Affinity DataIC50: 3.78nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631410(US20230348421, Compound 49)
Affinity DataIC50: 4.10nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631407(US20230348421, Compound 46)
Affinity DataIC50: 4.15nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631435(US20230348421, Compound 93)
Affinity DataIC50: 4.26nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596737(CHEMBL5191581 | US20230348421, Compound 41)
Affinity DataIC50: 4.29nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596728(CHEMBL5175451 | US20230348421, Compound 94)
Affinity DataIC50: 4.29nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596725(CHEMBL5198919 | US20230348421, Compound 92)
Affinity DataIC50: 4.64nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596726(CHEMBL5184906 | US20230348421, Compound 55)
Affinity DataIC50: 4.70nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631437(US20230348421, Compound 95)
Affinity DataIC50: 5.13nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631397(US20230348421, Compound 23)
Affinity DataIC50: 5.64nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631393(US20230348421, Compound 18)
Affinity DataIC50: 5.75nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631414(US20230348421, Compound 56)
Affinity DataIC50: 5.77nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596722(CHEMBL5172822 | US20230348421, Compound 78)
Affinity DataIC50: 6.01nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631397(US20230348421, Compound 23)
Affinity DataIC50: 6.02nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631415(US20230348421, Compound 57)
Affinity DataIC50: 6.41nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631428(US20230348421, Compound 77)
Affinity DataIC50: 6.44nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596725(CHEMBL5198919 | US20230348421, Compound 92)
Affinity DataIC50: 6.54nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631428(US20230348421, Compound 77)
Affinity DataIC50: 6.59nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631399(US20230348421, Compound 25)
Affinity DataIC50: 6.73nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631415(US20230348421, Compound 57)
Affinity DataIC50: 6.83nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596741(CHEMBL5185362 | US20230348421, Compound 26)
Affinity DataIC50: 6.86nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631394(US20230348421, Compound 19)
Affinity DataIC50: 6.94nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631406(US20230348421, Compound 45)
Affinity DataIC50: 7.04nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631410(US20230348421, Compound 49)
Affinity DataIC50: 7.30nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM50596728(CHEMBL5175451 | US20230348421, Compound 94)
Affinity DataIC50: 7.59nMAssay Description:NIH3T3-5HT2AR cells in the logarithmic growth phase were seeded into a white-wall clear-bottom 96-well plate at a density of 1000 cells per well, and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631432(US20230348421, Compound 89)
Affinity DataIC50: 7.72nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631421(US20230348421, Compound 65)
Affinity DataIC50: 7.98nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631423(US20230348421, Compound 70)
Affinity DataIC50: 8.09nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Geneora Pharma (Shijiazhuang) Co.

US Patent
LigandPNGBDBM631426(US20230348421, Compound 75)
Affinity DataIC50: 8.35nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 131 total ) | Next | Last >>
Jump to: